FDA OKs Lilly-Amylin Drug for Type 2 Diabetes
NEW YORK (Reuters) – U.S. regulators have approved a diabetes drug derived from lizard saliva for patients who have not responded to other treatments, the drug’s developers, Eli Lilly and Co. and Amylin Pharmaceuticals Inc., said on Friday.
This post does not allow comments
